Nazak Michael Adrian 4
4 · Aridis Pharmaceuticals, Inc. · Filed Jan 13, 2020
Insider Transaction Report
Form 4
Nazak Michael Adrian
Chief Financial Officer
Transactions
- Exercise/Conversion
Stock Options
2020-01-02+20,000→ 60,000 totalExercise: $4.45Exp: 2030-01-02→ Common Stock (20,000 underlying)
Footnotes (1)
- [F1]The stock options vest in equal installments over 48 months, beginning on January 2, 2020.